AYTU BIOPHARMA, INC (AYTU)
About AYTU BIOPHARMA, INC
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $66.4M
- Net income
- -$13.6M
- Total assets
- $124.2M
- Market cap
- $23.2M
- Gross margin
- 69.0%
- Operating margin
- -11.8%
- Net margin
- -20.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $66.4M
- Cost of revenue
- $20.6M
- Gross profit
- $45.8M
- Operating expenses
- $53.7M
- Operating income
- -$7.8M
- Income tax
- $437.0K
- Net income
- -$13.6M
- EPS (basic)
- $-2.16
Balance sheet
- Total assets
- $124.2M
- Current assets
- $79.2M
- Total liabilities
- $105.2M
- Current liabilities
- $63.1M
- Shareholders’ equity
- $19.0M
Cash flow
- Operating cash flow
- -$1.9M
- Investing cash flow
- -$2.6M
- Financing cash flow
- $15.4M
- Net cash flow
- $10.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $23.2M
- Shares outstanding
- 11.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 15, 2008
Aytu Biopharma, Inc (AYTU) Stock Price
- Reported a net loss of $13.6M in FY2025.
- Revenue grew 1% from FY2021 to FY2025.
- Gross margin of 69.0%, net margin -20.4%.
- Trading 26% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review AYTU BIOPHARMA, INC.
Write a review
News about AYTU BIOPHARMA, INC
News & sentiment via Polygon.io
Aytu Biopharma, Inc: frequently asked questions
Is Aytu Biopharma, Inc an American company?
Aytu Biopharma, Inc is a US-based company headquartered in Denver, Colorado, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Aytu Biopharma, Inc headquartered?
Aytu Biopharma, Inc is headquartered in Denver, Colorado, United States.
Is Aytu Biopharma, Inc publicly traded?
Yes — Aytu Biopharma, Inc is a publicly traded company. Its stock trades under the ticker symbol AYTU on the NASDAQ.
What does Aytu Biopharma, Inc do?
Aytu Biopharma, Inc is an American Pharmaceuticals company in the Health & Beauty sector.
